146 related articles for article (PubMed ID: 17383180)
1. Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.
Smith RA; Fathi Z; Achebe F; Akuche C; Brown SE; Choi S; Fan J; Jenkins S; Kluender HC; Konkar A; Lavoie R; Mays R; Natoli J; O'Connor SJ; Ortiz AA; Su N; Taing C; Tomlinson S; Tritto T; Wang G; Wirtz SN; Wong W; Yang XF; Ying S; Zhang Z
Bioorg Med Chem Lett; 2007 May; 17(10):2706-11. PubMed ID: 17383180
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
3. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptor antagonists and obesity.
Black SC
Curr Opin Investig Drugs; 2004 Apr; 5(4):389-94. PubMed ID: 15134279
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.
Hadcock JR; Griffith DA; Iredale PA; Carpino PA; Dow RL; Black SC; O'Connor R; Gautreau D; Lizano JS; Ward K; Hargrove DM; Kelly-Sullivan D; Scott DO
Biochem Biophys Res Commun; 2010 Apr; 394(2):366-71. PubMed ID: 20211605
[TBL] [Abstract][Full Text] [Related]
6. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
[TBL] [Abstract][Full Text] [Related]
7. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists.
Kim JY; Seo HJ; Lee SH; Jung ME; Ahn K; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Jan; 19(1):142-5. PubMed ID: 19022666
[TBL] [Abstract][Full Text] [Related]
8. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.
Plummer CW; Finke PE; Mills SG; Wang J; Tong X; Doss GA; Fong TM; Lao JZ; Schaeffer MT; Chen J; Shen CP; Stribling DS; Shearman LP; Strack AM; Van der Ploeg LH
Bioorg Med Chem Lett; 2005 Mar; 15(5):1441-6. PubMed ID: 15713403
[TBL] [Abstract][Full Text] [Related]
10. Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.
Smith RA; Fathi Z; Brown SE; Choi S; Fan J; Jenkins S; Kluender HC; Konkar A; Lavoie R; Mays R; Natoli J; O'Connor SJ; Ortiz AA; Podlogar B; Taing C; Tomlinson S; Tritto T; Zhang Z
Bioorg Med Chem Lett; 2007 Feb; 17(3):673-8. PubMed ID: 17107792
[TBL] [Abstract][Full Text] [Related]
11. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
Hagmann WK
Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
[TBL] [Abstract][Full Text] [Related]
12. 1-Sulfonyl-4-acylpiperazines as selective cannabinoid-1 receptor (CB1R) inverse agonists for the treatment of obesity.
Vachal P; Fletcher JM; Fong TM; Huang CC; Lao J; Xiao JC; Shen CP; Strack AM; Shearman L; Stribling S; Chen RZ; Frassetto A; Tong X; Wang J; Ball RG; Tsou NN; Hickey GJ; Thompson DF; Faidley TD; Nicolich S; Achanfuo-Yeboah J; Hora DF; Hale JJ; Hagmann WK
J Med Chem; 2009 Apr; 52(8):2550-8. PubMed ID: 19320488
[TBL] [Abstract][Full Text] [Related]
13. Novel thioamide derivatives as neutral CB1 receptor antagonists.
Boström J; Olsson RI; Tholander J; Greasley PJ; Ryberg E; Nordberg H; Hjorth S; Cheng L
Bioorg Med Chem Lett; 2010 Jan; 20(2):479-82. PubMed ID: 20005704
[TBL] [Abstract][Full Text] [Related]
14. CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders.
Antel J; Gregory PC; Nordheim U
J Med Chem; 2006 Jul; 49(14):4008-16. PubMed ID: 16821760
[No Abstract] [Full Text] [Related]
15. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
16. Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Alig L; Alsenz J; Andjelkovic M; Bendels S; Bénardeau A; Bleicher K; Bourson A; David-Pierson P; Guba W; Hildbrand S; Kube D; Lübbers T; Mayweg AV; Narquizian R; Neidhart W; Nettekoven M; Plancher JM; Rocha C; Rogers-Evans M; Röver S; Schneider G; Taylor S; Waldmeier P
J Med Chem; 2008 Apr; 51(7):2115-27. PubMed ID: 18335976
[TBL] [Abstract][Full Text] [Related]
17. Methylsulfonylpyrazolyl oxadiazoles and thiadiazoles as potent, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Seo HJ; Kim MJ; Song KS; Lee SH; Jung ME; Kim MS; Park HJ; Yoo J; Chang CH; Kim J; Lee J
Future Med Chem; 2009 Aug; 1(5):947-67. PubMed ID: 21426091
[TBL] [Abstract][Full Text] [Related]
18. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, SAR and intramolecular hydrogen bonding pattern of 1,3,5-trisubstituted 4,5-dihydropyrazoles as potent cannabinoid CB(1) receptor antagonists.
Lange JH; van der Neut MA; den Hartog AP; Wals HC; Hoogendoorn J; van Stuivenberg HH; van Vliet BJ; Kruse CG
Bioorg Med Chem Lett; 2010 Mar; 20(5):1752-7. PubMed ID: 20137935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
